Brooks Laboratories Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, following a Board Meeting held on February 6, 2026. The meeting, which concluded at 7:45 PM, also covered various strategic matters, including the issuance of equity shares on a preferential basis. For the quarter ending December 2025, the company reported a total income of ₹16.79 Crores, showcasing a significant jump compared to the corresponding period last year. Net profit for the period stood at ₹5.50 Crores, reflecting a robust growth of over 350% on a year-on-year basis. On a sequential basis, revenue saw a decline of approximately 29.5%, while profit jumped by 134.6% due to better operational efficiencies.

Financial Result Analysis (Q3 FY26)

Brooks Laboratories Limited, established in 2002, is a pharmaceutical contract research and manufacturing company specializing in the critical care segment. The company’s product portfolio includes a wide range of formulations such as Beta Lactam, Cephalosporins, and general dry powder injectables. It operates an EU-certified manufacturing facility in Vadodara and a facility in Baddi, catering to both domestic and international markets. In 2025, the company made significant strides, including receiving ITAT orders in January 2026 and announcing a merger of its associate company, Brooks Steriscience Limited, into OneSource Speciality Pharma Limited to enhance liquidity. Notably, Quant Mutual Fund holds a 9.9% stake in the company as of December 2025, marking them as a prominent institutional investor.